Hexarelin research peptide is a synthetic hexapeptide growth hormone secretagogue (GHS) that selectively targets and activates the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. Studied predominantly in preclinical pituitary cell assays and animal models, it is evaluated for its potent stimulation of growth hormone release and cardiac receptor binding properties.
Hexarelin research peptide is a synthetic hexapeptide growth hormone secretagogue (GHS) that selectively targets and activates the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. Studied predominantly in preclinical pituitary cell assays and animal models, it is evaluated for its potent stimulation of growth hormone release and cardiac receptor binding properties.
Hexarelin (chemically identified as His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide structurally derived from growth hormone-releasing peptide 6 (GHRP-6). By incorporating unnatural D-amino acids into its sequence, researchers engineered a peptide structure exhibiting enhanced enzymatic stability compared to endogenous peptide ligands. This molecular architecture allows researchers evaluating the hexarelin research peptide to observe distinct pharmacological characteristics in controlled experimental settings.
With a molecular formula of C47H58N12O6 and a molecular weight of approximately 887.04 g/mol, hexarelin possesses a stable backbone resistant to rapid aminopeptidase degradation. The inclusion of D-tryptophan and D-phenylalanine residues confers spatial conformations that optimize receptor binding affinity. In laboratory environments, high-purity lyophilized hexarelin appears as a white, sterile powder requiring proper storage and handling protocols to maintain structural integrity for analytical testing.
The primary mechanism of action for hexarelin centers on its high-affinity binding to the growth hormone secretagogue receptor type 1a (GHS-R1a), a seven-transmembrane G-protein-coupled receptor (GPCR). GHS-R1a is endogenously activated by ghrelin, an orexigenic peptide produced primarily in the gastrointestinal tract. When hexarelin binds to GHS-R1a on anterior pituitary somatotrophs, it initiates an intracellular signal transduction cascade driven by the Gq/11 protein subunit.
Activation of this pathway stimulates phospholipase C (PLC), facilitating the cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers the immediate release of intracellular calcium (Ca2+) from the endoplasmic reticulum into the cytoplasm. This localized surge in intracellular calcium drives the exocytosis of pre-stored growth hormone granules. Investigators utilizing our peptides for research examine these intracellular calcium flux kinetics to quantify secretagogue potency across distinct pituitary cellular models.
In preclinical literature, hexarelin is frequently documented as one of the most potent synthetic GH secretagogues within its chemical class. In vitro assays evaluating primary rat pituitary cell cultures demonstrate that hexarelin induces a rapid, dose-dependent release of growth hormone. Unlike endogenous growth hormone-releasing hormone (GHRH), which operates via the cyclic adenosine monophosphate (cAMP) pathway, hexarelin operates synergistically with GHRH, utilizing complementary intracellular messaging pathways to amplify somatotroph secretion.
Rodent and non-human primate research models demonstrate that hexarelin-induced GH release maintains partial resistance to inhibition by somatostatin (somatotropin release-inhibiting factor). Preclinical trials show that while somatostatin blunts GHRH-mediated GH release, hexarelin retains a substantial portion of its secretagogue activity even in the presence of elevated somatostatinergic tone. This unique property makes hexarelin a valuable reference compound in neuroendocrine research investigating pituitary regulation mechanisms.
Beyond its neuroendocrine actions via GHS-R1a, preclinical studies indicate that hexarelin exhibits distinct binding affinity for CD36, a class B scavenger receptor expressed in cardiac muscle, endothelial cells, and macrophages. CD36 plays a pivotal role in fatty acid transport, oxLDL clearance, and inflammatory signaling within vascular tissue. Hexarelin represents one of the few growth hormone secretagogues capable of dual action at both GHS-R1a and CD36 sites.
In vitro cardiac tissue assays and rodent ischemia-reperfusion models have explored hexarelin's cytoprotective capabilities. Research indicates that activation of cardiac CD36 and GHS-R1a receptors by hexarelin may modulate extracellular signal-regulated kinase (ERK1/2) and Akt signaling pathways. Preclinical studies suggest these biochemical interactions support cell survival, attenuate apoptosis, and reduce oxidative stress during hypoxic conditions in cultured cardiomyocytes, operating through mechanisms completely independent of systemic growth hormone elevation.
To contextualize hexarelin within growth hormone secretagogue research, investigators frequently run side-by-side comparative protocols alongside related hexapeptides and small molecules. Hexarelin displays higher acute secretagogue potency than Ipamorelin, yet exhibits distinct receptor desensitization profiles. While ipamorelin shows high selectivity for GHS-R1a without altering prolactin or cortisol levels in vitro, hexarelin demonstrates broader receptor interactions, including significant affinity for the peripheral CD36 receptor.
Compared to its parent molecule GHRP-6 and second-generation compounds like GHRP-2, hexarelin displays a lower propensity for stimulating appetite center pathways in rodent feeding assays. Furthermore, hexarelin demonstrates rapid receptor desensitization (tachyphylaxis) upon repeated continuous exposure in vitro compared to non-peptide growth hormone secretagogues like CJC-1295. Researchers selecting compounds from the catalog of research peptides must account for these receptor kinetic profiles when designing chronic versus acute dosing protocols.
Ensuring the integrity of hexarelin during laboratory preparation requires strict adherence to standardized aseptic reconstitution procedures. Lyophilized hexarelin should be allowed to equilibrate to room temperature inside a laminar flow hood before reconstitution to prevent condensation contamination. Sterile bacteriostatic water (containing 0.9% benzyl alcohol) or sterile normal saline (0.9% NaCl) serves as the standard solvent for preparing stock solutions.
When introducing the diluent, direct the stream against the glass vial wall rather than directly onto the peptide cake to prevent shear stress degradation. Gently swirl the vial in a smooth circular motion until the lyophilized powder is completely dissolved. Violent vortexing or mechanical agitation must be avoided, as it can induce protein aggregation or disrupt delicate peptide tertiary structures. Stock solutions prepared for in vitro assays should be aliquoted into sterile microcentrifuge tubes to prevent repeated thermal cycles.
The physical stability of hexarelin depends heavily on ambient temperature, exposure to light, and moisture exposure. In its original, unopened lyophilized state, hexarelin remains stable for up to 24 months when stored in a desiccated freezer environment at -20°C or -80°C. Storage at standard refrigeration temperatures (2°C to 8°C) is acceptable for short-term periods, provided the vial remains sealed against atmospheric moisture.
Once reconstituted into aqueous solution, hexarelin undergoes slow hydrolytic degradation over time. Reconstituted aliquots stored at 2°C to 8°C should generally be used within 28 days to ensure consistent experimental reproducibility. For long-term preservation of reconstituted stock, aliquots should be flash-frozen and maintained at -80°C. Repeated freeze-thaw cycles significantly accelerate peptide cleavage and aggregation, rendering the sample unsuitable for quantitative binding assays.
Maintaining experimental reproducibility requires utilizing hexarelin manufactured under rigid analytical control standards. PX1 Research subjects every lot of hexarelin to rigorous analytical evaluation, publishing lot-specific Certificates of Analysis (COAs) to verify physical and chemical purity. High-Performance Liquid Chromatography (RP-HPLC) with reverse-phase column separation is utilized to confirm chemical purity, ensuring an integration peak area exceeding 98.0%.
Electrospray Ionization Mass Spectrometry (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF) is conducted to verify exact molecular mass, confirming the absence of truncated sequences, deletion peptides, or synthesis byproducts. Furthermore, chromogenic Limulus Amebocyte Lysate (LAL) testing is performed to quantify bacterial endotoxin levels. PX1 Research guarantees endotoxin thresholds below 0.5 EU/mg, preventing endotoxin-mediated cellular toxicity or confounding inflammatory signaling in cell culture assays. For high-volume institutional sourcing, review our wholesale research accounts.
PX1 Research provides academic institutions, biotechnology firms, and contract research organizations (CROs) with high-purity research compounds synthesized under stringent domestic manufacturing guidelines. All products are manufactured in GMP-compliant facilities within the USA and verified by independent ISO 17025 accredited analytical laboratories prior to distribution.
To support rigorous research timelines, PX1 Research maintains centralized fulfillment operations out of California and Arizona. Orders placed Monday through Friday receive same-day dispatch, packaged in temperature-controlled, secure transport containers designed to maintain peptide stability throughout transit. Every vial shipped includes accessible, lot-matched COAs to ensure full analytical traceability for compliant laboratory documentation.
What is the primary receptor target of hexarelin research peptide?
Hexarelin acts as a potent agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), also known as the ghrelin receptor. Additionally, preclinical literature documents hexarelin binding affinity for the peripheral CD36 scavenger receptor expressed in cardiovascular tissues.
How is hexarelin supplied for laboratory research?
Hexarelin is supplied as a sterile, lyophilized (freeze-dried) powder in sealed glass vials. This format ensures long-term chemical stability during shipping and storage prior to laboratory reconstitution.
What solvent is recommended for reconstituting hexarelin for cell culture assays?
Sterile bacteriostatic water (0.9% benzyl alcohol) or sterile normal saline (0.9% NaCl) is recommended for reconstituting hexarelin. For specific in vitro cell assays where preservatives may interfere, sterile phosphate-buffered saline (PBS, pH 7.4) may be utilized.
What purity level is verified for PX1 Research hexarelin?
PX1 Research verifies that every batch of hexarelin achieves a chemical purity of ≥98.0%, as determined by Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) analytical testing.
Why is endotoxin testing critical for hexarelin research compounds?
Bacterial endotoxins (lipopolysaccharides) can trigger non-specific inflammatory responses in cell cultures and animal models, producing false-positive or irreproducible experimental results. PX1 Research verifies endotoxin levels are strictly below 0.5 EU/mg via LAL testing.
How does hexarelin compare to ipamorelin regarding receptor desensitization?
In preclinical receptor models, hexarelin exhibits faster rate of GHS-R1a receptor desensitization (tachyphylaxis) upon repeated exposure compared to ipamorelin, which maintains more stable signaling responses over prolonged exposure periods.
Can hexarelin be used for human health or therapeutic applications?
No. Hexarelin provided by PX1 Research is strictly designated for laboratory research use only (RUO), including in vitro cellular assays and preclinical animal models. It is not approved for human consumption, medical diagnosis, or therapeutic use.
What are the optimal storage conditions for long-term hexarelin stability?
Lyophilized hexarelin should be stored desiccated at -20°C or -80°C for long-term stability up to 24 months. Reconstituted liquid stock solutions should be aliquoted and kept at -80°C, avoiding repeated freeze-thaw cycles.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.